Publication | Open Access

The multi-receptor inhibitor axitinib reverses tumor-induced immunosuppression and potentiates treatment with immune-modulatory antibodies in preclinical murine models

Tumor-induced ImmunosuppressionMulti-receptor InhibitorImmune-modulatory AntibodiesMedicineImmunologyPharmacologyImmune Checkpoint InhibitorImmunomodulationImmunotherapyOncologyTumor MicroenvironmentCancer Research